Aygül ÇELTİK, Zalal ALATAŞ, Mümtaz YILMAZ, Meltem SEZİŞ DEMİRCİ, Gülay AŞCI, Mehmet ÖZKAHYA, Ercan OK

Ortalama trombosit hacmi ve ortalama trombosit hacmi/trombosit sayısı oranının periton diyalizi başlandıktan bir yıl sonraki değişimi

Amaç: Periton diyalizi yapan hastalarda en sık ölüm nedeni kardiyovasküler hastalıklardır. Trombosit aktivasyonunun göstergesi olan trombosit indeksleri ile kardiyovasküler olaylar arasında ilişki olduğu gösterilmiştir. Amacımız, son dönem böbrek hastalığı olan hastalarda periton diyalizi başlandıktan sonra trombosit sayısı, ortalama trombosit hacmi ve ortalama trombosit hacmi/trombosit sayısı oranının değişiminin incelenmesidir. Gereç ve Yöntemler: Bu retrospektif çalışmaya 28 hasta dahil edildi. Hastaların periton diyalizi başlandığı sıradaki demografik ve klinik özellikleri hasta dosyalarından kaydedildi. Periton diyalizi başlanmadan önce son bir ay içindeki ve başlandıktan sonra birinci yıldaki laboratuvar verileri kaydedildi. Ortalama trombosit hacmi/trombosit sayısı oranı, ortalama trombosit hacminin her mikrolitrede 1000 trombosit sayısına bölünmesi (ortalama trombosit hacmi/trombosit sayısı oranı=ortalama trombosit hacmi/her mikrolitrede 1000 trombosit sayısı) ile elde edildi. Bulgular: Hastaların yaş ortalaması 51.1 ± 14.6 idi. Hastaların %42.8’ i erkekti. Diyabetik ve hipertansif nefropati en sık son dönem böbrek hastalığı nedeniydi. Periton diyalizi başlandıktan bir yıl sonra C-reaktif protein düzeyi anlamlı olarak yükseldi. Periton diyalizi başlandıktan bir yıl sonra, trombosit sayısı 240 ± 55 x103/μL’ den 274 ± 53 x103/μL’ e yükseldi (p=0.003), ortalama trombosit hacmi 10.7 ± 1.0 fL’ den 10.2 ± 0.8 fL’ ye düştü (p

The change of mean platelet volume and mean platelet volume to platelet count ratio one year after iniation of peritoneal dialysis

Aim: Cardiovascular diseases are the most common cause of mortality in patients undergoing peritoneal dialysis. Thrombocyte indices which are indicators of platelet activation are predictors of cardiovascular events. We aim to examine the change in platelet count, mean platelet volume, and mean platelet volume to platelet count ratio one year after initiation of peritoneal dialysis in patients with end-stage renal disease. Materials and Methods: This retrospective study included 28 patients. Demographic and clinical characteristics of the patients at the time of initiation of peritoneal dialysis were recorded from the patient files. Laboratory data within the last month before the initiation of peritoneal dialysis and in the first year were recorded from the patient files. The mean platelet volume to platelet count ratio was calculated as mean platelet volume (femtolitres) divided by platelet count (number of thousand platelets/microliter). Results: The mean age was 51.1 ± 14.6 years, and 42.8% of the patients were male. Diabetic nephropathy and hypertensive nephropathy were the most common causes of end-stage renal disease. One year after the initiation of peritoneal dialysis, the urea level decreased significantly, and C-reactive protein level increased significantly. Platelet count increased from 240 ± 55 x10 3 /µL to 274 ± 53 x10 3 /µL (p=0.003) and mean platelet volume decreased from 10.7 ± 1.0 fl to 10.2 ± 0.8 fl (p

PDF

___

1. Collins AJ, Foley RN, Gilbertson DT, Chen SC. United States Renal Data System public health surveillance of chronic kidney disease and end-stage renal disease. Kidney Int Suppl (2011) 2015; 5 (1): 2-7.
2. Handtke S, Thiele T. Large and small platelets-(When) do they differ? J Thromb Haemost 2020; 18 (6): 1256- 67.
3. Rechciński T, Jasińska A, Foryś J et al. Prognostic value of platelet indices after acute myocardial infarction treated with primary percutaneous coronary intervention. Cardiol J 2013; 20 (5): 491-8.
4. Yavuz S, Ece A. Mean platelet volume as an indicator of disease activity in juvenile SLE. Clin Rheumatol 2014; 33 (5): 637-41.
5. Korniluk A, Koper-Lenkiewicz OM, Kaminska J, Kemona H, Dymicka-Piekarska V. Mean Platelet Volume (MPV): New Perspectives for an Old Marker in the Course and Prognosis of Inflammatory Conditions. Mediators Inflamm 2019; 2019: 9213074.
6. Chu SG, Becker RC, Berger PB et al. Mean platelet volume as a predictor of cardiovascular risk: a systematic review and meta-analysis. J Thromb Haemost 2010; 8 (1): 148-56.
7. Deveci S, Celebi A, Askin S, Gursoy AE, Kolukısa M, Hakyemez A. Akut iskemik inme ile ortalama trombosit hacmi ilişkisi. Ege Tıp Dergisi 2014; 53 (1): 6.
8. Molnar MZ, Streja E, Kovesdy CP et al. High platelet count as a link between renal cachexia and cardiovascular mortality in end-stage renal disease patients. Am J Clin Nutr 2011; 94 (3): 945-54.
9. Kim S, Molnar MZ, Fonarow GC et al. Mean platelet volume and mortality risk in a national incident hemodialysis cohort. Int J Cardiol 2016; 220: 862-70.
10.Peng F, Li Z, Yi C et al. Platelet index levels and cardiovascular mortality in incident peritoneal dialysis patients: a cohort study. Platelets 2017; 28 (6): 576-84.
11.Verdoia M, Barbieri L, Schaffer A, Bellomo G, Marino P, De Luca G. Impact of renal function on mean platelet volume and its relationship with coronary artery disease: A single-centre cohort study. Thromb Res 2016; 141: 139-44.
12. Zhu Y, Peng F, Chen Y et al. Mean platelet volume/platelet count ratio and mortality in patients on peritoneal dialysis Clin Nephrol 2018; 90 (3): 205-11.
13. Hedges SJ, Dehoney SB, Hooper JS, Amanzadeh J, Busti AJ. Evidence-based treatment recommendations for uremic bleeding. Nat Clin Pract Nephrol 2007; 3 (3): 138-53.
14. Gawaz MP, Dobos G, Späth M, Schollmeyer P, Gurland HJ, Mujais SK. Impaired function of platelet membrane glycoprotein IIb-IIIa in end-stage renal disease. J Am Soc Nephrol 1994; 5 (1): 36-46.
15. Linthorst GE, Folman CC, van Olden RW, von dem Borne AE. Plasma thrombopoietin levels in patients with chronic renal failure. Hematol J 2002; 3 (1): 38-42.
16. Gafter U, Bessler H, Malachi T, Zevin D, Djaldetti M, Levi J. Platelet count and thrombopoietic activity in patients with chronic renal failure. Nephron 1987; 45 (3): 207-10.
17.Arends JP, Krediet RT, Boeschoten EW, van der Lelie J, Veenhof CH, von dem Borne AE. Improvement of bleeding time, platelet aggregation and platelet count during CAPD treatment. Proc Eur Dial Transplant Assoc 1981; 18: 280-5.
18.Kennedy C, Wong L, Sexton DJ et al. Successful kidney transplantation normalizes platelet function. Clin Kidney J 2018; 11(4): 574-80.
19.Balduini CL, Noris P, Spedini P, Belletti S, Zambelli A, Da Prada GA. Relationship between size and thiazole orange fluorescence of platelets in patients undergoing high-dose chemotherapy. Br J Haematol 1999;106(1):202-7.
20.Senchenkova EY, Komoto S, Russell J et al. Interleukin-6 mediates the platelet abnormalities and thrombogenesis associated with experimental colitis. Am J Pathol 2013; 183 (1): 173-81.
21.Kamath S, Blann AD, Lip GY. Platelet activation: assessment and quantification. Eur Heart J 2001; 22 (17): 1561-71.
22. Zhao CN, Mao YM, Wang P et al. Lack of association between mean platelet volume and disease activity in systemic lupus erythematosus patients: a systematic review and meta-analysis. Rheumatol Int 2018; 38 (9): 1635-41.
23. Gupta J, Mitra N, Kanetsky PA et al. Association between albuminuria, kidney function, and inflammatory biomarker profile in CKD in CRIC. Clin J Am Soc Nephrol 2012 7 (12): 1938-46.
24.Stenvinkel P, Heimbürger O, Lindholm B, Kaysen GA, Bergström J. Are there two types of malnutrition in chronic renal failure? Evidence for relationships between malnutrition, inflammation and atherosclerosis (MIA syndrome). Nephrology Dialysis Transplantation 2000; 15 (7): 953-60.
25. Cho Y, Johnson DW, Vesey DA et al. Baseline serum interleukin-6 predicts cardiovascular events in incident peritoneal dialysis patients. Perit Dial Int 2015; 35 (1): 35-42.
26. Lambie M, Chess J, Donovan KL et al. Independent effects of systemic and peritoneal inflammation on peritoneal dialysis survival. J Am Soc Nephrol 2013; 24 (12): 2071-80.
27. Cho JH, Hur IK, Kim CD et al. Impact of systemic and local peritoneal inflammation on peritoneal solute transport rate in new peritoneal dialysis patients: a 1-year prospective study. Nephrol Dial Transplant 2010; 25 (6): 1964-73.